Thanks third quarter, and Kerry. therapeutics. the clinical to RNAi on execute DNAbilize on today. continue development innovative thank joining our us platform Good nanoparticle you across we Throughout our for morning, plans everyone
contains the As cohorts portion X and more I in later we two with prexigebersen the detail study patients decitabine. clinical will continued study have of of with treating are in The of describe completion Phase nearing call, safety the combination in patients.
AML syndrome and in high-risk refractory myelodysplastic patients. MDS and or first and myeloid cohort high-risk MDS leukemia the in AML The relapsed untreated acute patients; or second
venetoclax patients. combination venetoclax the in of and to decitabine Going evaluate forward, the triple add of we both cohorts of plan prexigebersen, to efficacy
a our technology. I platform will of review my with begin discussion
There integrate RNAi which has in structure delivered the the you with via drug toxicity of into with unique our been use anti-sense platform layers. therapeutics associated to cellular acid be the nucleic cell no proprietary DNAbilize for As cells our therapeutics. because to incorporation membrane, their nanoparticle DNAbilize the of technology, uptake anti-sense the high creation diseased into of evidence lipid the the technology. allowing with we know,
enthusiastic extremely novel for are need. suffering treatments high medical of DNAbilize platform We our from the disease for unmet developing about with patients potential
our we being Prexigebersen prexigebersen. progress studied X have in Phase the candidate of made for clinical the advancing review lead a product Let’s is AML. treatment trial
to in the incomplete achieved remission, with regimen. As standard who trial have trial The who or open-label AML elected a was in pharmacokinetics, The primary complete multi-center reminder, hematologic assess prexigebersen. recovery. patients this within low-dose a intensity novo and that combination recovery was intensity eligible otherwise two-stage cytarabine prexigebersen studied complete or study study a or not regimens originally de with previously profile, endpoint is for platelet a with remission pharmacodynamics chemotherapy including patients high LDAC low complete untreated of efficacy design the and safety of who are
assess vital the safety physical time clinical prexigebersen, to signs duration including endpoints by response and laboratory overall Secondary of adverse examination evaluated of and response, events as findings, and tests. efficacy survival,
our from complete results our bone Phase significantly Phase study. to from analysis blasts. interim were a first report of patient original of from we XXXX, quarter with X ongoing achieved had the XXXX, analysis reduced presented one study, patient results combination stable four In to that study. we during who remission patients form XX%, including the treatment, response April free status disease, additional interim X the of the evaluable four including showed marrow with had And and our patients and or XX% some leukemia In exciting patients one who the pleased showed
had XX% efficacy the XXXX, and in from X interim the a XX% responses, or free stable to showed results study. CRI including X and blasts. including the who disease complete The morphologic that XX% bone announced during recall, state the where of including marrow leukemia than quarter X evaluable we had results patients response, X may updated reduction had greater interim of you or As first achieved X updated XX response, XX% improved patients profile who
rate Importantly, for prexigebersen to X% with through our XX% of favorable treatment study this novo study rate X the a combination safety with to from CR interim a with these secondary AML investigation XX% its highly this treat. was of LDAC difficult was response class patients, treatment patients principle potential venetoclax by showed only X the the patients it therapy XX%, were for in These observed of de provides efficacy whereas prexigebersen an investigators, complete increased of profile at in of in Phase safety prexigebersen updated approval confidence AML patients The to patients. of The novo extremely for de AML recent an alone data treat benchmarked combining LDAC of frontline AML venetoclax patients. of our in opportunity that decided and profile. treatment was and the the for prexigebersen underscore class Stage
have before therapy. frontline we candidate view combination We ideal said prexigebersen as an with
to for the aim treatment is prexigebersen improve match leading with frontline options patients. Our to therapies
development those changes. clinical The reflects registration treatment a As our landscape for to the evolves, directed those as will to plans treatment we continue program prexigebersen AML advances. for respond for
as the Firstly, change refractory myelodysplastic X pre-amended of and refractory clinical MDS high-risk we existed now has of patients. high-risk with syndrome clinical or the with Phase is The of high-risk patients. MDS second but AML the key existing inclusion X two the addition the patients and cohort trial, first of comprised the relapsed patients cohorts AML relapsed patients, and AML X have Stage patients MDS untreated amended trial study amended restructured the trial, being in the Phase in patients
determining standard venetoclax decitabine prexigebersen X-patient completed evaluable cohort assessment goal add decitabine, an the efficacy of in The prexigebersen, safe interim to X patients of trial the with combination the least to of combination be therapy commence. of the combination, It will we to Once is patients whether the assessment combination care milligram for have the is at of segment statistical significance. the testing assessment venetoclax of study meter that to efficacy in of can cohorts decitabine. efficacy in plan venetoclax evaluating we decitabine include XX a study X of XX Phase Once safety and completed, with would combination anticipated both patients of prexigebersen, of study patients. safety amended or both at each this combination assess square a dose decitabine of evaluating the decitabine, patients evaluable cohorts current with of that prexigebersen, is The modify prexigebersen treatment exceeds of a per treatment. with in
U.S at Drug XX the such sites approval. Administration Food favorable or up be The for segment clinical the of to accelerated would data, FDA in the United the to Upon expected Bio-Path conducted trial efficacy and petition States. is
relapsed to and patient plus forward, AML. company clinical these MDS, refractory for directed accruals. decitabine potential plus the in the two result cohorts untreated in steps AML and MDS. AML cohorts Overall, Moving sites one of clinical an transformational intends study prexigebersen registration in venetoclax, for emphasis trial will our X other will evaluate Both on Europe with Phase
often and Phase touch including is would uterine our cancer solid is be I poor hormone our trial leading benefit and clinical programs, tumors, to trial centers that endometrial provide on briefly several to conducted outcomes ovarian prexigebersen advanced expected of initially to additional safety recurrent and may cancer. and evaluate plan like the turning refractory have and pancreatic ovarian This such with with efficacy cancer at endometrial cancer. clinical planned patients of diagnosed is ovarian and X hope Before and breast to with patients. our for prexigebersen starting Patients prexigebersen
expect our finalizing and study to are this XXXX. IND begin We in
the targets STATX for candidate preclinical our third review let’s BPXXXX, drug Next, data protein. the which
tumor Annual for to our Cancer the We in studies the the of in successfully tumors are efficacy from in BPXXXX frontline or penetrate BPXXXX results in standard derived Atlanta a studying at Previous American treatments. Research have of model. were presentation pancreatic the The April. shown enhance of Meeting preclinical Association treatment highlighted drug and AACR models poster pancreatic of patient
for typically of though cells. We vascular are cancer active cells or abilities well-recognized formation cells proliferate are uncontrollably, distant induce aberrantly and is a cancer. tumor of transcription-X invade cell transduction in activator The STATX to normal of and be excited in to STATX death, resist targeting organs or Signal inactive number reasons. apoptosis hallmarks
linked with lung found disease cancer, including is chemotherapy recently, as produce and has avoid advanced with levels. in clinical regulator immune a ductal standard capability Activation STATX field. types expected cancers, to point is the has clinical of tumors to acceptance chemotherapy, inhibition combination with has is which agent evasion cancer. of gemcitabine in critical pathways, resistance many the STATX, multiple STATX for many AML a pancreatic for of oncologic a cell and pancreatic and immune correlates by outcome, convergence of care STATX considered research of Activation including evade significant emerged also of processes. and poor system tumor in destruction mediator adenocarcinoma. cancer STATX been gained genes enhanced metastasis surveillance been at the has of immune in these high-grade benefit. Therefore, cancer to of involved More the non-small of a
XX and cancer An identified overall ex BPXXXX was STATX at anti-sense manufactured performed highlighted with RNAi activity of panel tissue technology. non-small AACR liposome patient-derived incorporated study four and sensitivity in gemcitabine. RNA directly oligo viability pancreatic by tests alone with conducted of to and AML anti-sense the in nanoparticle DNAbilize the lung cell xenografts a ductal western carcinoma determine blots antisense combination were to inhibitory assay cells. live on vivo of STATX sequences poster Cell messenger oligo The against using Bio-Path effects
previously P slice than value with less XX% Using a was inhibition tissue viability response. a defined greater .XX criteria, than
days. than in bearing XX volumes XX of vivo week significantly of patient a gemcitabine a gemcitabine further in BPXXXX by BPXXXX administered ex validation mice micromolars assay, of subset efficacy out a twice slice at dose cancer For cancer pancreatic in tissue The monitored for X vivo of tumor of inhibited days. combination the patient-derived to pancreatic XX enhanced sensitivity for XX xenografts In derived BPXXXX BPXXXX of up were of ex viability xenografts. more were XX%. Tumor xenografts tissue and the results,
gemcitabine a data drug from when patient-derived caused of the treatment earlier another we regression very and As encouraging drug very combination AACR, the XX ceased. period. tumor for during response enthusiastic even in this xenograft was universally audience. activity in had These XX-day maintained a cancer treatment where well-received This days study had the BPXXXX were anticancer vivo models, pancreatic with year
be in an therapy limited particularly cutting-edge cancer of treatment as this are that to this program our excited especially it We first has will launch human challenging validation options. in indication
antisense STATX in BPXXXX liposome-incorporated addition, as was potent In AML in demonstrated protein cell cells BPXXXX selected decreasing in cell viability. STATX non-small viability cancer cell validation sequence Further most the lung expression. that inhibited
preclinical tackling with for excited product platform. in data very forward IND technology be human with are to enabling tumors candidate XXXX in trials these with goal proprietary next some year. first solid our We to a would by studies our We and enter look promising BPXXXX this
Finally, candidate application we second domain. the for protein, patients pipeline and has anti-apoptotic which with patients lymphocytic for second in It chronic by investigational combination We works targets decitabine. BHX CLL IMD BCLX. BPXXXX. also candidate, updated neutralizing or new proteins AML therapeutic shown activity treatment our or is also improved Venetoclax have our an plans BPXXXX, for our BCLX filed drug recently an leukemia untreated the against and
the relapse over with due of invariably allergenic to cell occurs BHX some patients disease and transplantation, However, mutation oftentimes treated time. hemopoetic domain with exception
targets BPXXXX also protein. BCLX the
the BHX based activity domain. on blocking is BPXXXX the BCLX and messenger not However, RNA
that for treat could to treatments patients a As AML additional believe provide with those we opportunity could an believe venetoclax relapsed. have relapses BPXXXX patient representing alternative BPXXXX. from patients we who there result, to Further, be an venetoclax Bio-Path
treatments result, treating filed our occur. amend driven X in of AML with registration of Phase combination to give We we prexigebersen CLL relapses. relapses a those modification patients. venetoclax in including BCLX As The BPXXXX this early experience AML program include clinical patients us have will planned with can if these for registration venetoclax in include to anti-apoptosis
always, We medications. expect our and have evaluate to as opportunities to to study continue expand in other we And filed technology to an platform our begin DNAbilize first-in-human BPXXXX IND oncology year. next
capitalized well our execute candidates. three clinical plans our promising therapeutic to we Importantly, for development remain fully
a As number financing earlier now the milestones successful that significantly year, enhance achieve resources we this a shareholder our key result value. believe should to of have of we
with I balance third that, over turn With program along for now review Price to sheet will a Anthony? the Anthony financials highlights. of quarter brief our
